Santos García, DiegoDeus Fonticoba, Teresa deCores Bartolomé, CarlosFeal Painceiras, Maria J.Íñiguez Alvarado, Maria CristinaGarcía Díaz, IagoJesús, SilviaBuongiorno, Maria TeresaPlanellas, LluísCosgaya, MarinaGarcía Caldentey, JuanCaballol, NúriaLegarda, InesHernández Vara, JorgeCabo, IriaLópez Manzanares, LydiaGonzález Aramburu, IsabelÁvila Rivera, Maria A.Gómez Mayordomo, VíctorNogueira, VíctorPuente, VíctorDotor García-Soto, JulioBorrué, CarmenSolano Vila, BertaÁlvarez Sauco, MaríaVela, LydiaEscalante, SoniaCubo, EstherCarrillo Padilla, FranciscoMartínez Castrillo, Juan C.Sánchez Alonso, PilarAlonso Losada, Maria G.López Ariztegui, NuriaGastón, ItziarKulisevsky, JaimeMenéndez González, ManuelSeijo, ManuelRuiz Martínez, JavierValero, CaridadKurtis, MónicaGonzález Ardura, JessicaAlonso Redondo, RubenOrdás, CarlosLópez Díaz, Luis M.Mcafee, DarrianCalopa, MatildeCarrillo, FátimaEscamilla Sevilla, FranciscoFreire Alvarez, EricGómez Esteban, Juan CarlosGarcía Ramos, RocíoLuquín, María Rosario IsabelMartínez Torres, IreneSesar Ignacio, ÁngelMartinez Martin, PabloMir, PabloCOPPADIS Study Group2023-07-192023-07-192023-03-061877-718Xhttps://hdl.handle.net/2445/200872Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL: 1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Results: Four hundred and thirty-nine PD patients (62.05 +/- 7.84 years old; 59% males) were included. MNCD stage was: stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advanced MNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p < 0.0001) and EUROHIS-QOL8 (p < 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.24 p.application/pdfengcc by-nc (c) Santos García, Diego et. al.; 2023http://creativecommons.org/licenses/by-nc/3.0/es/Malaltia de ParkinsonQualitat de vidaSímptomesParkinson's diseaseQuality of lifeSymptomsinfo:eu-repo/semantics/article2023-06-20info:eu-repo/semantics/openAccess36911948